Physician profile
Christopher Wang
NPI 1275161838
$1,990.82
in general payments reported to CMS, 2019-2025
21 companies · $776 in 2025
The $776 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $421 · 2024: $794 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.84 |
| Education | $182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.69 | 2023-2025 | |
| Celgene Corporation | $246.30 | 2023-2025 | Reblozyl |
| Emd Serono, INC. | $194.09 | 2023-2025 | Bavencio |
| Genzyme Corporation | $181.70 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $168.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $162.75 | 2024-2025 | Keytruda |
| Incyte Corporation | $115.08 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Blueprint Medicines Corporation | $84.35 | 2024-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $72.74 | 2024-2025 | Ultomiris |
| Janssen Biotech, INC. | $53.80 | 2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $47.55 | 2024-2025 | Enhertu |
| Beone Medicines USA, INC. | $37.01 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $33.49 | 2024 | |
| Jazz Pharmaceuticals INC. | $32.96 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $32.79 | 2025 | Onivyde, Somatuline Depot |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $31.67 | 2025 | |
| Exelixis INC. | $31.46 | 2025 | Cabometyx |
| Genentech USA, INC. | $26.21 | 2024 | Phesgo, Tecentriq, Tecentriq Hybreza |
| Sumitomo Pharma America, INC. | $22.41 | 2025 | Orgovyx |
| Astrazeneca Pharmaceuticals Lp | $17.24 | 2024 | Lynparza |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.